|
|
|
|
||||
|
|
|
|
|
|||
|
|
|
|
|
|
|
AbstractDO.18.07 Immunosuppression in risk keratoplasty Birnbaum F., Reinhard T. Immune reactions are still the leading cause for graft failure following penetrating keratoplasty, especially in high-risk situations such as vascularization of the recipient cornea, graft position close to the limbus or repeat-keratoplasty. Midterm systemic immunosuppression in addition to the topical immunosuppression with steroids following risk keratoplasty is widely used in Germany and should be standard of care. To date, predominantly cyclosporine A (CSA) und mycophenolate mofetil (MMF) are administered. Superiority of systemic MMF compared to only topical treatment with steroids was demonstrated in a recent clinical trial. Due to considerable side effects of systemic immunosuppression, the development of a potent topical immunomodulating therapy is desirable. FK506-eyedrops could be an option or new approaches like subconjunctival drug delivering devices or topically applied antiangiogenic substances. |
|||
| Previous page Top of page |
|
|
|
|
|